128 results

• FDA Issues Additional Tazverik Blood Cancer Warnings After Market Recall

  May 15, 2026

  Irvin Jackson

  Federal regulators have concluded that Tazverik blood cancer rates make the lymphoma drug a bigger risk to patients' health than its benefits, urging providers to stop its use immediately.

• Truqap Side Effects Linked to Discontinuation Risks, FDA Staffers Warn

  May 1, 2026

  Irvin Jackson

  FDA drug experts warned a panel of scientific advisors that Truqap’s toxicity has been linked to a high number of treatment discontinuations, as the manufacturer seeks approval to expand use of the breast cancer drug for prostate cancer.

• Study Finds No Link Between Side Effects of GLP-1s and Thyroid Cancer

  February 24, 2026

  Irvin Jackson

  A new report dismisses concerns linking drugs like Ozempic and Mounjaro to increased thyroid cancer risks, despite the drugs carrying a black box warning from the FDA.

• Andexxa Recall Announced After FDA Says Xarelto, Eliquis Reversal Agent Risks Outweigh Benefits

  December 22, 2025

  Irvin Jackson

  AstraZeneca is removing its blood thinner reversal agent Andexxa from the market after the FDA determined the drug's blood clot risks outweigh its benefits.

• Ocaliva Market Withdrawal To Take Final Effect on Nov. 14

  October 21, 2025

  Irvin Jackson

  The recalled liver disease drug Ocaliva will no longer be available to patients after November 14, following its rejection by the FDA over liver injury risks.

• Ocaliva Recall Issued Due to Liver Injury Risks

  September 12, 2025

  Irvin Jackson

  Intercept has announced it is removing the liver disease drug Ocaliva from the market after the FDA determined it does more harm than good.

• Skysona Blood Cancer Side Effects Lead to New FDA Restrictions

  August 11, 2025

  Martha Garcia

  The FDA has added a black box warning to the gene therapy drug Skysona after discovering more patients developed blood cancer than previously believed.

• FDA Warns of Ocaliva Liver Injury Risks Linked to Autoimmune Disorder Drug

  December 13, 2024

  Martha Garcia

  Federal regulators warns that the autoimmune treatment Ocaliva has been linked to liver damage and failure, resulting in patient deaths and the need for transplants.

• Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis

  November 21, 2024

  Irvin Jackson

  Safety concerns linked to Andexxa, the reversal agent for newer blood thinners like Xarelto and Eliquis, will be discussed at an FDA advisory panel meeting today, after postmarketing studies indicated the drug doubled the risks of blood clots and death.

• Eli Lilly Claims Kisunla Brain Swelling Side Effects Can Be Reduced With Modified Dosing Schedule

  November 4, 2024

  Irvin Jackson

  Makers of the new Alzheimer's disease drug Kisunla have developed a new dosing schedule, which may reduce the risk of brain swelling.